News

01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development and maximize the value of its MPS1 Inhibitor Asset, NMS-01940153E (NMS-153).
(Click the title for the complete article)

January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline. Terrence West, MBA, joins as New Business, Virtual CEO.
(Click the title for the complete article)

MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
(Click the title for the complete article)

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)

A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of NMS-153. A highly potent and selective inhibitor of the MPS1 kinase, NMS-153 is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC. Please read the press release here! 
(Click the title for the complete article)

NMS Group S.p.A. announces the appointment of Mr. Emiliano Sala as Chief Financial Officer, effective immediately. Mr. Sala is a highly accomplished CFO with broad finance and business experience at several large organizations, including in healthcare, where he has led financial planning, turnaround and business process management. He joins NMS Group to lead the business control and administrative team, reporting directly to the Chief Executive Officer. He will be part of the Executive Leadership Team.  
(Click the title for the complete article)

NMS today announced that Salvatore Marengoni Galdy, M.D., has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. Dr. Galdy will drive values of our assets through planning and leading the clinical development to meet all time, quality, budget, Company standards and scientific requirements.
(Click the title for the complete article)

Nerviano, 19, October 2022_NMS Group S.p.A., the largest oncological R&D company in Italy, announced the appointment of Mr. Lincoln Pan to its Board of Directors, effective immediately.

“We are pleased to welcome my PAG colleague Lincoln to the NMS Group Board,” said David Wong, chairman of NMS Group. “Lincoln’s deep experience in increasing the value of our global investments with strong financial oversight will be invaluable to NMS Group as we continue to grow our business.”
(Click the title for the complete article)